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Abstract—Novel 1,4-benzodiazepine compounds were synthesized and evaluated for their ability to inhibit the proliferation of tumor 
cells. Some compounds revealed activities in the micromolar range and were more efficient than reference compound Ro 5-4864. 
Preliminary SAR helped to identify critical motifs for antiproliferative activity and led to the discovery of a compound selective of a 
melanoma cell-line, known for its resistance to chemotherapy. 
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Benzodiazepines are widespread compounds used for 
the treatment of mental disorders. A few years ago, 
some of these compounds showed antiproliferative 
properties against some tumor cell lines. This 
highlights them as potential anticancer agents.1,2  
We are presently resorting to the 1,4-benzodiazepine 
scaffold, a suitable template for combinatorial 
chemistry3, to design small inhibitors of STAT3 
dimerization. STAT3 (Signal Transducer and 
Activator of Transcription 3) plays a key role in 
cancer, by regulating as a dimer the expression of anti-
apoptotic or pro-survival genes.4 Dimerization occurs  
upon phosphorylation on its Tyr705, through 
reciprocal interaction between the SH2 (Src 
Homology 2) domain of STAT3 and the pTyr residue. 
On the basis of preliminary molecular modelling based 
on the X-ray crystal structure of STAT35, the N-1 
position on the 1,4-benzodiazepine structure (Figure 
1) was used to substitute phosphate or phosphonate 
analogues, mimicking the role of pTyr in its SH2 
domain interaction. The C-3 position was used to 
introduce a basic substituent to probe the effect of a 
possible ionic interaction with the SH2 domain. 
The compounds were evaluated by an ELISA test for 
their ability to disrupt in vitro STAT3 dimerization but 
showed no significant activity. Nevertheless,  they 
were further evaluated for their possible 
antiproliferative activities on two STAT3-dependent 
cell lines, NIH 3T3/v-Src cells6 and melanoma cells 
A20587, as well as on Hela cells, a cervical carcinoma 
tumor cell line, whose growth is not dependent on 
STAT3.8  
Here, we report the synthesis and biological evaluation 
of our derivatives. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of the 1,4-benzodiazepine compounds. 
 
 
H
AL author m
anuscript    inserm
-00168656, version 1
HAL author manuscript
Bioorganic & Medicinal Chemistry Letters 17, 9 (2007) 2527-30
 - 2 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. (a) TFFH, DIEA, CH2Cl2, rt; (b) i-20%TFA/CH2Cl2 for 3 or 
H2/Pd-C, MeOH for 4; ii- 5%AcOH in CH2Cl2, reflux. 
 
The synthesis of the diazepine core is described in 
Scheme 1. Peptidic coupling of 2-aminobenzophenone 
with suitably protected alanine or lysine could be 
achieved by the in situ formation of acyl-fluoride9 
compounds with the use of 
tetramethylfluoroformamidinium hexafluorophosphate 
(TFFH) to give 1 and 2 in 69-85% yields. Boc and 
Cbz protecting groups were completely removed 
respectively by treatment with 20% trifluoroacetic 
acid (TFA) in methylene chloride and by Pd-catalyzed 
hydrogenolytic cleavage.  
Cyclization to obtain the diazepine core was achieved 
using 5% of acetic acid in methylene chloride to give 
3 and 4 in quantitative yield.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. (a) Dibenzylphosphite, DIEA, CCl4, DMAP, CH2Cl2, -15°C, 
(b) CBr4, PPh3, CH2Cl2, rt; (c) Boc2O, Na2CO3, THF, rt; (d) NBS, 
dibenzoylperoxyde, CCl4, reflux. 
 
The preparation of two brominated derivatives 
necessary for the N-alkylation of the core diazepine is 
described in Scheme 2. 4-hydroxybenzylalcohol was 
treated with dibenzylphosphite10 to give 
dibenzylprotected phosphate derivative 5 in 70% 
yield. Transformation of the benzyl alcohol 5 to the 
bromide derivative 6 was achieved in 63% yield using 
triphenylphosphine and carbon tetrabromide.11  
Bromide 8 was obtained by Boc-protecting p-cresol 
followed by N-bromosuccinimide (NBS) bromination 
in 65% yield. The 4-(di-tert- 
butylphosphonomethyl)benzylbromide used to 
synthesize 10 and 13 was prepared as previously 
described.12 
Alkylation of diazepines 3 and 4 (Scheme 3) with 
benzyl bromide derivatives in the presence of the mild 
base cesium carbonate13 afforded 9-13 in 80-90% 
yields. Final compounds 16, 17 and 20 were obtained 
in quantitative yield, by treatment with 50% TFA in 
methylene chloride for 3h. Under such conditions, 
compounds 9 and 12 gave monobenzyl-protected 
compounds 14 and 18, and the unprotected analogs 15 
and 19 in about equal proportions. 
 
 
Scheme 3. (a) Cs2CO3, CH2Cl2, rt; (b) 50%TFA/CH2Cl2, rt. 
 
The lack of inhibitory effects of these benzodiazepines 
against STAT3 dimerization led us to investigate if 
alternatively, and in line with the findings reported in 
the litterature14, they could inhibit Src kinase activity. 
However, no inhibitory effect was found in the case of 
the present compounds. 
 
Nevertheless, in cell assays, some of the 
benzodiazepine derivatives demonstrated efficient 
antiproliferative activities, inhibiting cell growth with 
IC50 in the micromolar range. 
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Table 1. Antiproliferative activity against tumor cell lines 
 
 
 
 
 
 
 
 
Compound R4 R5 IC50 ± SEM (µM)a
   NIH 3T3/v-Srcb A2058c HeLac
Ro 5-486417 - - 31.9 ± 4.4 ≥ 100 ≥ 100 
3 
  
N-1 unsubstituted n.ad n.a n.a 
14 
  
 
49.5 ± 3.2 61.5  ± 7.9 40.5 ± 0.5 
15  
 
36.6 ± 5.9 28.9 ± 1.5 21.3 ± 1.7 
16 
 
  
n.a n.a n.a 
17 
  
 38.6 ± 3.5 27.2 ± 0.3 29.3 ± 0.6 
19  
 
≥ 80 33.8 ± 0.5 ≥ 80 
20  
  
n.a n.a n.a 
a IC50 values expressed with standard error. 
b Cell growth determined by counting cells with a particle counter. 15
c Cytotoxic activity determined by a WST-1 test. 16
d Showed no activity at 150 µM. 
  
Cell growth inhibition was first evaluated on v-Src 
transformed mouse fibroblasts.15 The cytotoxic 
activity of all the compounds was then tested against 
two human tumor cell lines, A2058 and HeLa cells, 
using a WST-1 colorimetric test.16 Results are given in 
Table 1. In addition, the benzodiazepine Ro 5-4864 
(4’-chlorodiazepam), whose antiproliferative activity 
has already been demonstrated against some             
tumor cell lines
                                                                         We therefore investigated if a hydroxyl group could be 
sufficient to retain activity. 4-hydroxylated compound 
17 was accordingly synthesized and was found to be 
as efficient as the phosphate analogue 15. These data 
indicate that the presence of an oxygen atom seems 
critical for antiproliferative activity. Moreover, they 
suggest that it may be possible to optimize potency 
with other O-substituted compounds. On the other 
hand, the most potent compounds (14, 15 and 17) were 
also active on HeLa cells, indicating that they 
probably do not target the STAT3 pathway. 
17-19, was also evaluated as the 
reference compound. 
 
These data indicate that whilst the unsubstituted 
benzodiazepine 3 is inactive towards any of the three 
cell types, some of our substituted benzodiazepines are 
more efficient than reference compound Ro 5-4864, 
on both human tumor cell lines. 
N-1 unsubstituted compound 3 showed no 
antiproliferative activity towards any of the three cell 
types, indicating that further substitutions are 
necessary for biological activity.  
For the C-3 methyl series (R4 = CH3), N-substitution 
with a p-phosphorylated benzyl moiety improved 
activity in each cell type with IC50 in the micromolar 
range (15). Monobenzyl-protected phosphate 
derivative 14, initially synthesized to improve cell 
penetration, was less potent than the free phosphate 
analog 15 against the three cell types. Interestingly, 
phosphate replacement with phosphonate abrogated 
biological activity in each cell type. The higher pKa 
value of phosphonate derivative may be the cause for 
the loss of activity.20 The presence of an oxygen atom 
at the p-position on the benzyl ring may also be 
important. 
 
For the C-3 aminobutyl series (R4 = (CH2)4NH2), the 
phosphonate derivative 20 was also inactive. These 
data confirmed the importance of a                      
phenolic group or a p-phosphorylated benzyl moiety. 
Monobenzyl-protected phosphate derivative 18 could 
not be tested because of low solubility. Surprisingly, 
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introduction of a basic alkyl chain in C-3 position led 
to a compound (19) rather selective of melanoma cells, 
with only weak potency on the two other cell types. 
 
In the literature, other benzodiazepines, such as Ro 5-
4864, have been shown to have antiproliferative 
activity, most of the time via an undefined or uncertain 
mechanism.17-19 Whilst PBR (Peripheral 
Benzodiazepine Receptor) has been reported to be a 
possible target18,19, benzodiazepine derivative Bz-423 
has recently been found to induce antiproliferative 
activity independent of the PBR.21  
Thus, to our knowledge, the present work reports one 
of the first SAR studies, regarding the effects of 
substitution on both N-1 and C-3 position, on 
antiproliferative properties of 1,4-benzodiazepines. 
Although our compounds did not inhibit STAT3 
dimerization in the Src-STAT3 pathway, they 
displayed interesting antiproliferative activities against 
different tumor cell lines. Benzodiazepines 14, 15 and 
17 were even more efficient than reference compound 
Ro 5-4864 on both human tumor cell lines. 
Preliminary SAR helped us to identify critical motifs 
for activity and led to the discovery of a compound 
selective for a melanoma cell line, known for its 
resistance to chemotherapy.22  
 
In conclusion, these two series of benzodiazepines are 
promising leads for the development of anticancer 
agents. Further experiments will be done to identify 
their physiological target and improve the potency and 
the selectivity of both series of compounds. 
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